Onconova Therapeutics Surges in Pre-Market After Announcing Pre-approval Access Collaboration With Inceptua Medicines Access for Rigosertib in Selected Countries Outside the US

NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), and Inceptua Medicines Access (a business unit of the Inceptua Group), a global pharmaceutical […]

Aurinia (NASDAQ: AUPH) Skyrockets After Announcing Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

We are thrilled with the outcomes reported today from the AURORA trial, which unequivocally demonstrate the tremendous potential for voclosporin to play an important role in the treatment of the approximately one million people worldwide living with LN” – Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and […]

ChemoCentryx Soars 337% After Announcing Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis with VFMCRP

“We are delighted with the positive topline data from the Phase III ADVOCATE trial for the treatment of ANCA vasculitis,” — Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks —   — Significantly reduced […]

Top 3 Biotech/Pharma Breakout Stocks

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 94.4%) Sorrento Therapeutics (NASDAQ: SRNE) closed up 94.4% at $3.11 on NASDAQ with record volume of 75.02 million shared traded. The company reported that they rejected an offer to be acquired by two pharmaceutical companies for between $3.00 and $5.00 per share in cash. JanOne […]

JanOne Soars 55% Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD)

Phase 2b testing planned for PAD treatment and PAD-associated pain to address 8.5 million patient US market LAS VEGAS, Nov. 25, 2019 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, […]

%d bloggers like this: